What is the recommended management of checkpoint inhibitor–induced cardiotoxicity?

Management of Checkpoint Inhibitor-Induced Cardiotoxicity

Hold checkpoint inhibitor therapy immediately for any grade of cardiac toxicity and permanently discontinue after even grade 1 cardiac complications, then initiate high-dose corticosteroids (1-2 mg/kg prednisone) rapidly while admitting the patient for cardiology consultation. 1

Immediate Actions for Suspected Cardiotoxicity

Discontinue Therapy

• Permanently discontinue checkpoint inhibitors for all grades of cardiac complications, including grade 1. 1
• The appropriateness of rechallenge remains unknown and is generally not recommended given the life-threatening nature of cardiovascular complications. 1

Initiate Corticosteroids Immediately

• Administer high-dose corticosteroids (1-2 mg/kg prednisone or equivalent) rapidly, either oral or IV depending on symptom severity. 1
• For grade 2 or higher, early initiation (within 24 hours) of high-dose corticosteroids is likely beneficial without adverse effects. 1
• Continue corticosteroids until resolution of symptoms and normalization of troponin, left ventricular systolic function, and conduction abnormalities. 1

Hospital Admission and Cardiology Consultation

• Admit the patient immediately and obtain urgent cardiology consultation. 1
• Transfer immediately to coronary care unit for patients with elevated troponin or conduction abnormalities. 1
• Active, ongoing consultation with cardiology to discuss risk/benefit of treatments cannot be overstated. 2

Diagnostic Workup

Essential Cardiac Testing

• ECG to detect QTc prolongation, new conduction disease, ST-T wave changes, or arrhythmias. 1, 2
• Cardiac troponin measurement (troponin I is more specific than troponin T when skeletal muscle disease is present). 1, 2
• BNP or NT-pro-BNP levels (levels >500 pg/ml indicate significant concern). 1, 2
• Echocardiogram with global longitudinal strain assessment. 1
• Chest X-ray. 1

Advanced Imaging

• Cardiac MRI is necessary if clinical syndrome suggests myocarditis, cardiac troponin is elevated, or ECG shows abnormalities. 1, 2
• Endomyocardial biopsy should be considered if diagnosis is highly suspected with otherwise negative workup. 1

Additional Laboratory Testing

• C-reactive protein and viral titers to evaluate for alternative diagnoses. 1
• Serial troponin monitoring if initially elevated—recheck troponin 6 hours later. 1
• Normal cardiac enzymes cannot always rule out myocarditis, making comprehensive evaluation essential even when initial biomarkers appear reassuring. 2

Escalation for Steroid-Refractory Cases

High-Dose Pulse Corticosteroids

• For patients without immediate response to standard high-dose corticosteroids, institute cardiac transplant rejection doses of corticosteroids (methylprednisolone 1 gram daily). 1

Additional Immunosuppressive Agents

• Add mycophenolate, infliximab, or antithymocyte globulin (ATG) for steroid-refractory cases. 1
• Consider abatacept (costimulatory molecule blockade) or alemtuzumab (CD52 blockade) as additional immunosuppression in life-threatening cases. 1
• Critical caveat: Infliximab is contraindicated at high doses (>5 mg/kg) in patients with moderate-severe heart failure. 1
• Prospective data suggest systematic screening for respiratory muscle involvement, coupled with active ventilation, prompt use of abatacept, and addition of ruxolitinib may decrease mortality. 3

Management According to ACC/AHA Guidelines

Standard Cardiac Care

• Manage cardiac symptoms according to American College of Cardiology/American Heart Association guidelines with cardiology guidance. 1
• Provide guideline-directed medical therapy for cardiomyopathy and/or heart failure as indicated. 1
• Provide appropriate medical and supportive care for atrial or ventricular tachyarrhythmia or heart block as indicated. 1
• Consider pacemaker for new conduction delay. 1

Hemodynamic Support

• Seek respiratory and hemodynamic support for severe cases. 1

Special Considerations

Triple M Syndrome

• Be aware of the potential for triple M immune-related adverse events—myositis, myasthenia, and myocarditis—particularly with elevated troponin. 1, 2
• Bulbar symptoms (dysphagia, dysarthria, dysphonia), respiratory failure, ptosis, diplopia, or dropped head syndrome may indicate myositis severity or associated myasthenia gravis (present in 12.5% of cases). 2
• Creatine kinase elevation is seen in the majority of myositis patients (median 2650 IU/L). 2

Timing and Risk Factors

• Cardiovascular immune-related adverse events occur in <0.1% of patients receiving checkpoint inhibitors based on pharmaceutical safety databases. 1
• Myocarditis with cardiac involvement typically occurs early after checkpoint inhibitor initiation (median 25 days, IQR 25-45 days). 2
• Risk may be increased with combination therapy (ipilimumab and nivolumab: 0.28% vs nivolumab alone: 0.06%). 1
• Mortality from myocarditis remains high at approximately 37.7%, justifying aggressive monitoring and management. 3

Evidence Strength

Treatment recommendations are based on anecdotal evidence and the life-threatening nature of cardiovascular complications, as cardiovascular immune-related adverse events are rare but potentially fatal. 1 Data are sparse and generally include case reports or small case series, with death frequently secondary to refractory arrhythmia or cardiogenic shock. 1